Business
Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report
Ji’an, Jiangxi, China, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that on February 19, 2025, the Company received a staff determination notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended September 30, 2024 (the “Form 20-F”) and
About this update from Universe Pharmaceuticals Inc
[{"type":"image","alt":"Universe Pharmaceuticals INC.","displaySize":"","headline":null,"caption":"Universe Pharmaceuticals INC.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/3cb73f0a0403d670c726d5e1fe0768b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tsxU1QTlL3X6huL1OC04ow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3cb73f0a0403d670c726d5e1fe0768b1","width":300,"height":80}},"lazy":false},{"type":"text","content":"Ji’an, Jiangxi, China, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that on February 19, 2025, the Company received a staff determination notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended September 30, 2024 (the “Form 20-F”) and that this matter serves as an additional basis for delisting the Company’s securities from Nasdaq. The failure to timely file the Form 20-F is a violation of Nasdaq Listing Rule 5250(c)(1).","length":689,"tagName":"p"},{"type":"text","content":"The Company is before a Hearings Panel for its failure to comply with Listing Rule 5550(a)(2) and was therefore provided until February 26, 2025 to request a stay of the suspension of the Company’s securities, pending a Hearings Panel decision. The Company intends to request a stay of the suspension before that date. The Company is working on completing and filing the delayed Form 20-F.","length":389,"tagName":"p"},{"type":"text","content":"This announcement is being made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.","length":153,"tagName":"p"},{"type":"text","content":"About Universe Pharmaceuticals INC","length":34,"tagName":"p"},{"type":"text","content":"Universe Pharmaceuticals INC, headquartered in Ji’an, Jiangxi, China, is a pharmaceutical producer and distributor in China. The Company specializes in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions ...